Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00166413
Status:
COMPLETED
Last Update Posted:
2011-05-06
First Post:
2005-09-12
Brief Title:
Efficacy of CC-5013 Revlimid or Lenalidomide in Patients With Primary Systemic Amyloidosis
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with primary systemic amyloidosis will be treated with CC-5013 lenalidomide Revlimid as a single agent for 3 months If their disease worsens or does not improve during that time frame dexamethasone will be added to the treatment program
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MC0484 | OTHER | None | None |
| 1105-04 | OTHER | Mayo Clinic IRB | None |